Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steve D Wilton

Showing results (51-60 of 109) with videos related to

Pageof 11
Sort By:
Frontiers in Pharmacology|April 8, 2022
Investigating the Implications of <i>CFTR</i> Exon Skipping Using a <i>Cftr</i> Exon 9 Deleted Mouse ModelKelly M Martinovich, Anthony Kicic, Stephen M Stick, et al.
BMC Medical Genetics|October 22, 2011
Mismatched single stranded antisense oligonucleotides can induce efficient dystrophin splice switchingClayton T Fragall, Abbie M Adams, Russell D Johnsen, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|October 22, 2009
Prevention of dystrophic pathology in severely affected dystrophin/utrophin-deficient mice by morpholino-oligomer-mediated exon-skippingAurélie Goyenvalle, Arran Babbs, Dave Powell, et al.
The Journal of Gene Medicine|November 15, 2005
Dystrophin expression in the mdx mouse after localised and systemic administration of a morpholino antisense oligonucleotideSusan Fletcher, Kaite Honeyman, Abbie M Fall, et al.
Frontiers in Neuroscience|December 24, 2019
ALS Genetics, Mechanisms, and Therapeutics: Where Are We Now?Rita Mejzini, Loren L Flynn, Ianthe L Pitout, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|March 25, 2010
Dystrophin isoform induction in vivo by antisense-mediated alternative splicingSue Fletcher, Abbie M Adams, Russell D Johnsen, et al.
Molecular Therapy. Nucleic Acids|December 31, 2018
Antisense Oligonucleotides Targeting Angiogenic Factors as Potential Cancer TherapeuticsBao T Le, Prithi Raguraman, Tamer R Kosbar, et al.
International Journal of Molecular Sciences|August 29, 2024
Is Exon Skipping a Viable Therapeutic Approach for Vascular Ehlers-Danlos Syndrome with Mutations in <i>COL3A1</i> Exon 10 or 15?Sasiwimon Utama, Jessica M Cale, Chalermchai Mitrpant, et al.
Journal of Neuromuscular Diseases|September 5, 2017
Efficient Skipping of Single Exon Duplications in DMD Patient-Derived Cell Lines Using an Antisense Oligonucleotide ApproachNicolas Wein, Adeline Vulin, Andrew R Findlay, et al.
Biomedicines|June 2, 2021
Targeted <i>SMN</i> Exon Skipping: A Useful Control to Assess In Vitro and In Vivo Splice-Switching StudiesLoren L Flynn, Chalermchai Mitrpant, Abbie Adams, et al.
Pageof 11

Showing results (51-60 of 109) with videos related to

Sort By:
Pageof 11
Frontiers in Pharmacology|April 8, 2022
Investigating the Implications of <i>CFTR</i> Exon Skipping Using a <i>Cftr</i> Exon 9 Deleted Mouse ModelKelly M Martinovich, Anthony Kicic, Stephen M Stick, et al.
BMC Medical Genetics|October 22, 2011
Mismatched single stranded antisense oligonucleotides can induce efficient dystrophin splice switchingClayton T Fragall, Abbie M Adams, Russell D Johnsen, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|October 22, 2009
Prevention of dystrophic pathology in severely affected dystrophin/utrophin-deficient mice by morpholino-oligomer-mediated exon-skippingAurélie Goyenvalle, Arran Babbs, Dave Powell, et al.
The Journal of Gene Medicine|November 15, 2005
Dystrophin expression in the mdx mouse after localised and systemic administration of a morpholino antisense oligonucleotideSusan Fletcher, Kaite Honeyman, Abbie M Fall, et al.
Frontiers in Neuroscience|December 24, 2019
ALS Genetics, Mechanisms, and Therapeutics: Where Are We Now?Rita Mejzini, Loren L Flynn, Ianthe L Pitout, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|March 25, 2010
Dystrophin isoform induction in vivo by antisense-mediated alternative splicingSue Fletcher, Abbie M Adams, Russell D Johnsen, et al.
Molecular Therapy. Nucleic Acids|December 31, 2018
Antisense Oligonucleotides Targeting Angiogenic Factors as Potential Cancer TherapeuticsBao T Le, Prithi Raguraman, Tamer R Kosbar, et al.
International Journal of Molecular Sciences|August 29, 2024
Is Exon Skipping a Viable Therapeutic Approach for Vascular Ehlers-Danlos Syndrome with Mutations in <i>COL3A1</i> Exon 10 or 15?Sasiwimon Utama, Jessica M Cale, Chalermchai Mitrpant, et al.
Journal of Neuromuscular Diseases|September 5, 2017
Efficient Skipping of Single Exon Duplications in DMD Patient-Derived Cell Lines Using an Antisense Oligonucleotide ApproachNicolas Wein, Adeline Vulin, Andrew R Findlay, et al.
Biomedicines|June 2, 2021
Targeted <i>SMN</i> Exon Skipping: A Useful Control to Assess In Vitro and In Vivo Splice-Switching StudiesLoren L Flynn, Chalermchai Mitrpant, Abbie Adams, et al.
Pageof 11